Osaka Medical College
π―π΅Japan
- Country
- π―π΅Japan
- Ownership
- Private, Subsidiary
- Employees
- -
- Market Cap
- -
- Website
- http://www.osaka-med.ac.jp
Clinical Trials
186
Active:0
Completed:125
Trial Phases
5 Phases
Phase 1:3
Phase 2:9
Phase 3:2
+2 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (179 trials with phase data)β’ Click on a phase to view related trials
Not Applicable
164 (91.6%)Phase 2
9 (5.0%)Phase 1
3 (1.7%)Phase 3
2 (1.1%)Phase 4
1 (0.6%)Neoadjuvant Nab-PTX and Trastuzumab for ER Negative and HER2 Positive Breast Cancer
Phase 2
Terminated
- Conditions
- Estrogen Receptor Negative NeoplasmBreast CancerHER-2 Positive Breast Cancer
- Interventions
- First Posted Date
- 2015-11-05
- Last Posted Date
- 2019-08-28
- Lead Sponsor
- Osaka Medical College
- Target Recruit Count
- 30
- Registration Number
- NCT02598310
- Locations
- π―π΅
Osaka Medical College, Takatsuki, Osaka, Japan
Primary Chemotherapy With Anthracycline Followed by Nab-paclitaxel and Trastuzumab
Phase 2
Completed
- Conditions
- Breast CancerHER-2 Positive Breast CancerEffects of Chemotherapy
- Interventions
- First Posted Date
- 2011-09-12
- Last Posted Date
- 2015-04-22
- Lead Sponsor
- Osaka Medical College
- Target Recruit Count
- 46
- Registration Number
- NCT01432223
- Locations
- π―π΅
Osaka Medical College, Takatsuki, Osaka, Japan
S-1 and Bevacizumab in Treating Patients With Colorectal Cancer That is Recurrent or Cannot Be Removed by Surgery
Phase 2
- Conditions
- Colorectal Cancer
- First Posted Date
- 2009-09-10
- Last Posted Date
- 2013-08-12
- Lead Sponsor
- Osaka Medical College
- Target Recruit Count
- 40
- Registration Number
- NCT00974389
- Locations
- π―π΅
Osaka Medical College, Takatsuki, Osaka, Japan
News
No news found